Posts

Patients Scramble to Find Estrogen Patches as Shortage Worsens After US FDA Champions Use

A surge in demand since last year for estrogen patches to ease menopause symptoms has strained supplies and led to shortages, sparking a scramble for medicines that industry... Reuters Health Information source https://www.medscape.com/s/viewarticle/patients-scramble-find-estrogen-patches-shortage-worsens-2026a1000av8?src=rss

Real-World Data Show Avacopan Safety Signals in Vasculitis

Avacopan shows a favorable safety profile in ANCA-associated vasculitis in real-world settings, with hepatobiliary events as the leading safety concern and no adverse events of high clinical priority. Medscape Medical News source https://www.medscape.com/viewarticle/real-world-data-avacopan-reveal-safety-signals-2026a1000auc?src=rss

Neuroimmunome Predicts Viral Hepatitis Severity

A neuroimmune gene signature detectable in blood and liver predicts viral hepatitis severity, suggesting nervous-immune crosstalk drives disease progression and informs monitoring. Medscape News Europe source https://www.medscape.com/viewarticle/neuroimmunome-predicts-viral-hepatitis-severity-2026a1000asw?src=rss

Early Relapse Signals High-Risk Primary Refractory LBCL

A secondary analysis of a phase 3 trial suggests that patients with relapse within 3 months of treatment or persistent disease represent a distinct high-risk group. Medscape Medical News source https://www.medscape.com/viewarticle/early-relapse-signals-high-risk-primary-refractory-lbcl-2026a1000as0?src=rss

On-Site Hepatitis C Care Boosts Treatment Uptake

On-site hepatitis C virus testing and treatment with peer support at opioid treatment programs boosts access to curative therapy and sharply increases treatment initiation. Medscape Medical News source https://www.medscape.com/viewarticle/site-hepatitis-c-care-boosts-treatment-uptake-2026a1000anb?src=rss

Australia Bans Use of Genetic Testing Data by Life Insurers

Australia has banned life insurance companies from using genetic testing information to deny or restrict policies. Medscape News Australia source https://www.medscape.com/viewarticle/australia-bans-use-genetic-testing-information-life-insurers-2026a1000anj?src=rss

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer. Medscape Medical News source https://www.medscape.com/viewarticle/circulating-tumor-dna-guided-adjuvant-therapy-cuts-bladder-2026a1000amx?src=rss